Sentiment-Signal
11,7
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Unternehmen & Branche
| Name | BELITE BIO, INC |
|---|---|
| Ticker | BLTE |
| CIK | 0001889109 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | ADR |
| Marktkapitalisierung | 6,18 Mrd. USD |
| Beta | -1,22 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -222 | 157.49 | -34,962.11 | -55,9% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -120 | 160.27 | -19,232.90 | -30,7% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -89 | 161.72 | -14,393.14 | -23,0% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -62 | 158.71 | -9,840.06 | -15,7% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -54 | 162.14 | -8,755.69 | -14,0% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -53 | 156.61 | -8,300.42 | -13,3% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -12 | 154.65 | -1,855.76 | -3,0% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -8 | 155.36 | -1,242.87 | -2,0% | |
| 2026-04-28 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -380 | 159.42 | -60,579.30 | -96,8% | |
| 2026-04-27 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -409 | 163.56 | -66,894.94 | -106,9% | |
| 2026-04-27 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -280 | 161.62 | -45,253.91 | -72,3% | |
| 2026-04-27 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -231 | 162.38 | -37,509.20 | -59,9% | |
| 2026-04-27 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -44 | 160.83 | -7,076.72 | -11,3% | |
| 2026-04-27 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -36 | 164.07 | -5,906.58 | -9,4% | |
| 2026-04-24 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -3 | 162.53 | -487.59 | -0,8% | |
| 2026-04-24 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -28 | 161.22 | -4,514.20 | -7,2% | |
| 2026-04-24 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -375 | 159.46 | -59,797.54 | -95,6% | |
| 2026-04-24 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -330 | 160.40 | -52,931.31 | -84,6% | |
| 2026-04-24 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -190 | 158.65 | -30,142.89 | -48,2% | |
| 2026-04-24 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -74 | 157.86 | -11,681.98 | -18,7% | |
| 2026-04-23 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -54 | 168.43 | -9,095.43 | -14,5% | |
| 2026-04-23 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -373 | 167.37 | -62,430.61 | -99,8% | |
| 2026-04-23 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -267 | 164.47 | -43,914.40 | -70,2% | |
| 2026-04-23 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -158 | 165.38 | -26,129.39 | -41,8% | |
| 2026-04-23 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -127 | 166.56 | -21,153.23 | -33,8% | |
| 2026-04-23 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -21 | 169.56 | -3,560.69 | -5,7% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -75 | 170.58 | -12,793.75 | -20,4% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -257 | 171.62 | -44,105.06 | -70,5% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -21 | 173.04 | -3,633.86 | -5,8% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -249 | 172.49 | -42,950.03 | -68,6% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -20 | 166.32 | -3,326.40 | -5,3% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -141 | 167.42 | -23,606.30 | -37,7% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -105 | 169.52 | -17,799.98 | -28,4% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -101 | 168.64 | -17,032.19 | -27,2% | |
| 2026-04-22 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -31 | 165.70 | -5,136.73 | -8,2% | |
| 2026-04-21 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -312 | 166.49 | -51,943.57 | -83,0% | |
| 2026-04-21 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -64 | 163.49 | -10,463.67 | -16,7% | |
| 2026-04-21 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -78 | 164.60 | -12,838.85 | -20,5% | |
| 2026-04-21 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -214 | 167.34 | -35,810.46 | -57,2% | |
| 2026-04-21 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -332 | 165.49 | -54,943.84 | -87,8% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -3 | 166.91 | -500.72 | -0,8% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -524 | 163.52 | -85,684.11 | -136,9% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -284 | 162.76 | -46,222.48 | -73,9% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -124 | 164.40 | -20,385.71 | -32,6% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -40 | 165.29 | -6,611.74 | -10,6% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -16 | 167.17 | -2,674.64 | -4,3% | |
| 2026-04-20 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -9 | 168.35 | -1,515.15 | -2,4% | |
| 2026-04-17 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -52 | 159.38 | -8,287.96 | -13,2% | |
| 2026-04-17 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -274 | 161.41 | -44,226.12 | -70,7% | |
| 2026-04-17 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -226 | 160.55 | -36,283.71 | -58,0% | |
| 2026-04-17 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -216 | 162.48 | -35,096.39 | -56,1% | |
| 2026-04-17 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -200 | 163.33 | -32,665.00 | -52,2% | |
| 2026-04-17 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -32 | 158.46 | -5,070.60 | -8,1% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -36 | 163.21 | -5,875.60 | -9,4% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -240 | 161.61 | -38,786.33 | -62,0% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -219 | 159.81 | -34,999.09 | -55,9% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -216 | 158.28 | -34,188.13 | -54,6% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -201 | 160.35 | -32,229.85 | -51,5% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -76 | 162.26 | -12,332.05 | -19,7% | |
| 2026-04-16 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -12 | 164.12 | -1,969.48 | -3,1% | |
| 2026-04-15 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -8 | 170.77 | -1,366.12 | -2,2% | |
| 2026-04-15 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -537 | 168.64 | -90,562.04 | -144,7% | |
| 2026-04-15 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -383 | 167.58 | -64,182.83 | -102,6% | |
| 2026-04-15 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -68 | 169.15 | -11,502.36 | -18,4% | |
| 2026-04-15 | MATA NATHAN L. | Officer, Chief Scientific Officer | Open Market Sale | -4 | 171.19 | -684.76 | -1,1% | |
| 2026-04-09 | Chuang Hao-Yuan | Director, Officer, Chief Financial Officer | Open Market Sale | -1,909 | 182.58 | -348,541.78 | -556,9% | |
| 2026-04-09 | Lin Yu-Hsin | Director, Officer, Chief Executive Officer | Open Market Sale | -3,500 | 181.33 | -634,656.40 | -1014,1% | |
| 2026-04-09 | Lin Yu-Hsin | Director, Officer, Chief Executive Officer | Open Market Sale | -3,000 | 182.40 | -547,188.00 | -874,4% | |
| 2026-04-09 | Lin Yu-Hsin | Director, Officer, Chief Executive Officer | Open Market Sale | -2,500 | 180.36 | -450,894.50 | -720,5% | |
| 2026-04-09 | Lin Yu-Hsin | Director, Officer, Chief Executive Officer | Open Market Sale | -200 | 183.00 | -36,600.00 | -58,5% | |
| 2026-04-09 | Chen Wan-Shan | Director | Open Market Sale | -1,100 | 180.43 | -198,473.11 | -317,1% | |
| 2026-04-09 | Chuang Hao-Yuan | Director, Officer, Chief Financial Officer | Open Market Sale | -2,000 | 181.40 | -362,790.00 | -579,7% | |
| 2026-04-09 | Chuang Hao-Yuan | Director, Officer, Chief Financial Officer | Open Market Sale | -2,000 | 180.35 | -360,695.00 | -576,4% | |
| 2026-04-09 | Chuang Hao-Yuan | Director, Officer, Chief Financial Officer | Open Market Sale | -291 | 183.08 | -53,276.66 | -85,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.